May 15, 2014
A Maryland federal judge on Wednesday found that Classen Immunotherapies Inc.'s claims that Biogen Idec Inc. infringed its patents for evaluating a vaccine immunization schedule were objectively baseless, dismissing Biogen from the case and granting its request for attorneys' fees.
August 09, 2012
A Maryland federal judge on Thursday told GlaxoSmithKline PLC that it couldn't use the U.S. Supreme Court's recent Prometheus decision to dismiss Classen Immunotherapies Inc.'s lawsuit alleging the pharmaceutical giant infringed a patented infant immunization process.
May 30, 2012
A Maryland federal judge on Tuesday refused to dismiss the bulk of a case against GlaxoSmithKline PLC alleging the pharmaceutical giant infringed Classen Immunotherapies Inc.'s patents for evaluating a vaccine immunization schedule, while tossing contributory and willful infringement claims.